I came to different conclusion after digesting the data presented at AAIC 2016 and CTAD 2016. A2-73 is the CURE. There at the onset of analyzing we have to return to the division of subjects into two groups. Namely, A2-73+DPZ 25 patients initially and A2-73 Alone 7 or 8 patients. This is essential in understanding the impact of the presented data on the claim to cure or near cure AD.
In AAIC data there was graph of MMSE score from 0 to 31 weeks. Between 18 and 31 week there was a surge in scores for the A2-73 alone group. I ploted the data and you can view the plot by going to my twitter account @piotrpietrzkiew. What it revealed was that initially the MMSE score went moderately down then stabilized and suddenly surged up. I expected some positive outcome in the soon to be released data. As it was, in the CTAD data there was no distinction between A2-73 Alone and A2-73+DPZ. Data presented on the 6 patients called MMSE Strong almost identical in shape and value at 31 weeks seemed to continue where the A2-73 Alone data stopped. Are these two one and the same? But the crux of the matter is in the shape of curves. We have initial down trend then uptrend to up steep incline,the uptrend happens in 18-24 weeks, followed by stabilization for 24 weeks and most recently nascent second surge when the score value at 57 weeks reaches up to 130 percent of score of just 4 weeks ago. It is entirely possible that within 24 weeks the score at this rate might hoover in vicinity of 28-30 MMSE. That certainly deserves the name of a cure.
If you look at the graph of DPZ you see gain in scores followed by steady decline, this isn't behavior of a complex system, and your brain is one. It is plasticity is amazing recall the people afflicted with stroke when part of brain dies and they have to relearn speaking or walking. Another example yet less dramatic is when you learn new skill and suddenly everything falls in place because your brain has reorganized itself to master the task.
Human brain is a complex system when the conditions change sufficiently it reorganizes itself and new functional performance is exhibited. This phenomenon is present in the data on A2-73 Alone/MMSE Strong patients. It indicates that something very fundamental happened to thoses neurons and the performance of the whole system after a delay transformed almost in a moment. In complex systems it is called an emerging property which appears after even small widespread change in the agents, read neurons.
The combined data for All Patients as ploted on the graphs traces the path taken by those dosed with placebo as documented in number of studies. From the purely math point A2-73+DPZ does worse than placebo.
It seems that the company does not want to scream "Here it is!". The prove is in the data but not made apparent. The reasons for that can be miriad but I will not speculate about that as it is beyond my competence.
Please, see my graphs on twitter atpiotrpietrzkiew.
News 
Market Data 
Discover 
